Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004
Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016
A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Achieving guideline-based asthma control: does the patient benefit? Source: Eur Respir J 2002; 20: 588-596 Year: 2002
Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007
Efficacy of fluticasone on cough: a randomised controlled trial Source: Eur Respir J 2005; 25: 147-152 Year: 2005
Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design Source: ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019 Year: 2019
Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice Source: Eur Respir J 2001; 18: Suppl. 33, 348s Year: 2001
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Is overall asthma control being achieved? A hypothesis-generating study Source: Eur Respir J 2001; 17: 589-595 Year: 2001
Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study Source: International Congress 2018 – COPD management Year: 2018
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
A pilot audit of primary care outcomes one year before and one year after starting a fluticasone / salmeterol combination Source: Eur Respir J 2002; 20: Suppl. 38, 112s Year: 2002
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021